Rheumatoid arthritis. Rheumatoid arthritis, unspecified
Conditions
Interventions
Intervention 1: The case group will receive two glasses of chamomile tea, containing 3 grams chamomile (plus 3 grams bran) brewed in 150 ml of water every day for six consecutive weeks. Chamomile flow
Treatment - Other
Placebo
The case group will receive two glasses of chamomile tea, containing 3 grams chamomile (plus 3 grams bran) brewed in 150 ml of water every day for six consecutive weeks. Chamomile flowers will be drie
The control group as placebo will receive two tea bags containing 3 grams of wheat bran as placebo every day for six consecutive weeks. The placebo packing will be done in the tea company. All the pat
Sponsors
Vice Chancellor for Research, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1) Subjects diagnosed with rheumatoid arthritis, based on American College of Rheumatology (ACR-2010) criteria; 2) Patients with moderate and less rheumatoid arthritis score (DAS-28<5.1); 3) Stable medication for at least 3 weeks prior to the intervention and during that; 4) Willing to participate in the study and giving written consent ; 5) Ages between 20 and 65; 6) Have a body mass index (BMI) less than 30 and more than 18.5 Exclusion criteria: 1) Pregnant and lactating women; 2) Patients with cardiovascular, lung, hepatic, kidney and blood diseases; 3) Having chronic inflammatory diseases such as Sjogern, Sicca, Multiple sclerosis, Lupus Erythematosus and Hashimoto’s diseases; 4) Patients with gastroduodenal ulcer; 5) Patients with a high sensibility to the experimental drugs; 6) Patients participating in another study just 3 weeks before the intervention; 7) Taking any vitamin, mineral or omega 3 supplement 3 months before the intervention.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intelukin 1-ß (IL-1ß), Tumor Necrosis Factor-alpha(TNF-alpha). Timepoint: At baseline and after 6 weeks of intervention. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Matrix metalloproteinase 3 (MMP-3). Timepoint: At baseline and after 6 weeks of intervention. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Saeed Pirouzpanah
Faculty of Nutrition, Tabriz University of Medical Sciences
Outcome results
None listed